Moderna’s cancer vaccine is ‘likely’ to get approved. Skeptics question if it will be the best option.
Published . Updated .
The first Phase 3 data for a custom cancer vaccine has raised questions about whether the potential new treatment is needed.
Directly affected
- MRNA Moderna+36.4%
Named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| MRNA | +13.36% | +22.89% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
The first Phase 3 data for a custom cancer vaccine has raised questions about whether the potential new treatment is needed.
Source: MarketWatch
This story
| Company | When | Move | Status |
|---|---|---|---|
| GLD | three days earlier | +3.37% | final price |
| GLD | five days earlier | +3.56% | final price |
| MRNA | three days earlier | +22.89% | final price |
| MRNA | five days earlier | +13.36% | final price |
| QQQ | three days earlier | +2.99% | final price |
| QQQ | five days earlier | +2.00% | final price |
| SPY | three days earlier | +1.75% | final price |
| SPY | five days earlier | +0.89% | final price |
| TLT | three days earlier | -1.35% | final price |
| TLT | five days earlier | -2.31% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 30 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 57 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Moderna’s cancer vaccine is ‘likely’ to get approved. Skeptics question if it will be the best option.” scores 12 out of 100. The score uses 1 sources.